Novelty in the development of biodegradable polymer coatings for biomedical devices: paclitaxel grafting on PDMMLA derivatives.

Autor: Gholizadeh E; Institut Galilée, Laboratory for Vascular Transitional Science (LVTS), Université Sorbonne Paris Nord, Villetaneuse, France., Naim M; Smbh, Laboratory for Vascular Transitional Science (LVTS), Université Sorbonne Paris Nord, Bobigny, France., Belibel R; Université Sorbonne Paris Nord, KymiaNova, Châtenay Malabry, France., Hlawaty H; Smbh, Laboratory for Vascular Transitional Science (LVTS), Université Sorbonne Paris Nord, Bobigny, France., Barbaud C; Institut Galilée, Laboratory for Vascular Transitional Science (LVTS), Université Sorbonne Paris Nord, Villetaneuse, France.
Jazyk: angličtina
Zdroj: Designed monomers and polymers [Des Monomers Polym] 2022 Mar 20; Vol. 25 (1), pp. 64-74. Date of Electronic Publication: 2022 Mar 20 (Print Publication: 2022).
DOI: 10.1080/15685551.2022.2054116
Abstrakt: Biocompatible and biodegradable polymers are widely used in the medical field. In some cases, the biopolymer is accompanied by an active drug, which is delivered locally in a controlled manner in order to improve the healing conditions. Poly([R,S]-3,3-dimethylmalic acid) (PDMMLA) is a synthetic amphiphilic biodegradable polymer, which unlike PLA, can be chemically modified to adapt hydrophilic/hydrophobic balance, degradation kinetics, and physicochemical and biological properties. It may contain a lateral alkyl group or a functional group for coupling bioactive molecules to release during its degradation. In this work, we realized the chemical grafting of paclitaxel (PTX), a microtubule stabilizing anti-cancer agent on PDMMLA derivatives bio-polyesters following a Steglich esterification protocol. 1D and 2D NMR analyses validated the reaction with 10% (using 0.1 equivalent) of PTX on the copolymer PDMMLAH 40 - co -Hex 60 (PDMMLA 40/60) and a maximal PTX grafting rate of 55% on the homopolymer PDMMLAH (PDMMLA 100/0). In vitro adhesion and cytotoxicity assays were carried out on HUVEC cells with PDMMLA 40/60, PDMMLA-PTX 30/10/60 and PLA.
Competing Interests: No potential conflict of interest was reported by the author(s).
(© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje